Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease
J M Olver, J M Olver
Abstract
Background/aim: Patients with thyroid eye disease with upper eyelid retraction often develop overaction of the accessory muscles of eyelid closure, the glabellar muscles corrugator supercilii and procerus. The resultant glabellar furrowing (frown lines) contributes to the typical thyroid facies. The aim of this study was to evaluate the use of botulinum toxin A reversible chemodenervation of the glabellar muscles as adjunctive treatment in the rehabilitation of patients with thyroid eye disease.
Methods: 14 patients (13 females) ages 39-76 years (mean 52) with inactive thyroid eye disease and associated medial eyebrow ptosis and prominent glabellar frown lines were recruited. All patients had a history of upper eyelid retraction. Each patient was treated with a single botulinum toxin injection (Dysport 0.2 ml, 40 units) into each corrugator supercilii and sometimes procerus muscles as an outpatient procedure. The effectiveness and acceptability of the treatment was assessed clinically and from a patient questionnaire.
Results: The injections were tolerated by 13/14 (93%) patients. There was resultant flattening of the glabellar region and improvement of medial eyebrow contour in all patients, with onset of paralysis within 1 week. All patients reported a subjective improvement in appearance. Side effects included one patient (7%) with reversible partial ptosis. The beneficial effect lasted 4-6 months, with a gradual return of function. Repeat treatment was indicated where there was persistent upper eyelid retraction and protractor overaction.
Conclusion: Botulinum toxin A chemodenervation of the glabellar muscles in these patients was effective and acceptable. Chemodenervation should be considered in the rehabilitation of patients with thyroid eye disease where there is upper eyelid retraction and overacting protractors resulting in a thyroid frown. Once the eyelid retraction has been successfully treated by surgery, the need for further glabella muscle chemodenervation is considerably reduced.
Figures
References
- Trans Am Ophthalmol Soc. 1981;79:734-70
- Plast Reconstr Surg. 1995 Jun;95(7):1170-7
- Arch Ophthalmol. 1984 Oct;102(10):1464-8
- Ophthalmology. 1996 Apr;103(4):618-22
- Surv Ophthalmol. 1996 Jul-Aug;41(1):51-65
- Arch Ophthalmol. 1985 Mar;103(3):347-50
- Am J Ophthalmol. 1985 May 15;99(5):542-6
- Am J Ophthalmol. 1985 Aug 15;100(2):305-7
- Ophthalmology. 1986 Jul;93(7):917-23
- Can J Neurol Sci. 1987 Feb;14(1):42-5
- Br J Ophthalmol. 1987 Sep;71(9):664-8
- Adv Neurol. 1988;49:493-500
- Eye (Lond). 1987;1 ( Pt 5):603-8
- Plast Reconstr Surg. 1988 Jul;82(1):48-57
- Br J Ophthalmol. 1988 May;72(5):361-2
- Adv Neurol. 1988;50:599-608
- J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):767-72
- Ophthalmology. 1988 Nov;95(11):1535-42
- Plast Reconstr Surg. 1989 Mar;83(3):546-54
- Plast Reconstr Surg. 1989 Aug;84(2):353-5
- Arch Dermatol. 1989 Aug;125(8):1090-2
- Ophthal Plast Reconstr Surg. 1986;2(3):143-6
- Can J Ophthalmol. 1991 Apr;26(3):133-8
- J Dermatol Surg Oncol. 1992 Jan;18(1):17-21
- Plast Reconstr Surg. 1994 Apr;93(5):913-8
- Plast Reconstr Surg. 1994 Jul;94(1):94-9
- Plast Reconstr Surg. 1995 May;95(6):993-1003; discussion 1004-6
- Arch Ophthalmol. 1982 Jun;100(6):981-6
Source: PubMed